By Emmanuel Bobby

A pharmaceutical manufacturer has issued a sweeping voluntary recall of more than 3 million bottles of over-the-counter eye drops after federal regulators raised concerns about product sterility — a critical safety standard for medications applied directly to the eyes.

The recall, which began in early March, affects 3,111,072 bottles produced by K.C. Pharmaceuticals, a California-based company that manufactures eye care products for multiple store-brand and private-label retailers.

According to the Food and Drug Administration, the action was taken due to a “lack of assurance of sterility,” meaning there is uncertainty about whether the products were manufactured and handled in a way that guarantees they are free from harmful contamination.

Eye drops are particularly sensitive products because they are applied directly to the العين, where even minor contamination can lead to irritation, infection, or more serious complications.

The affected products were widely distributed and sold at major pharmacy chains and retailers, including CVS, Walgreens, and Rite Aid, making the recall especially broad in scope.

What the Recall Means

The FDA has classified the action as a Class II recall, which is used in situations where exposure to a product may cause temporary or medically reversible health effects, but where the likelihood of serious harm is considered relatively low.

Importantly, a Class II designation does not automatically require consumers to stop using the product immediately unless specifically instructed by the manufacturer or health authorities. However, health experts generally advise caution when sterility is in question, particularly for products used in sensitive areas like the eyes.

As of now, there have been no confirmed reports of injuries or adverse reactions linked to the recalled eye drops.

The exact cause of the sterility concern has not been publicly disclosed, and the manufacturer has not provided additional details about what triggered the recall.

List of Recalled Eye Drop Products

The recall spans several formulations commonly used to treat dryness, redness, and irritation. Affected products include:

• Sterile Eye Drops AC (tetrahydrozoline HCl 0.05%, zinc sulfate 0.25%) – 0.5 fl oz (15 mL)
• Eye Drops Advanced Relief (dextran 70 0.1%, polyethylene glycol 400 1%, tetrahydrozoline HCl 0.05%) – 0.5 fl oz (15 mL)
• Dry Eye Relief Eye Drops (glycerin 0.2%, hypromellose 0.2%, polyethylene glycol 400 1%) – 0.5 fl oz (15 mL)
• Ultra Lubricating Eye Drops (polyethylene glycol 400 0.4%, propylene glycol 0.3%) – 0.5 fl oz (15 mL)
• Sterile Eye Drops Original Formula (tetrahydrozoline HCl 0.05%) – 0.5 fl oz (15 mL)
• Sterile Eye Drops Redness Lubricant (glycerin 0.25%, naphazoline HCl 0.012%) – 0.5 fl oz (15 mL)
• Sterile Eye Drops Soothing Tears (polyethylene glycol 400 0.4%, propylene glycol 0.3%) – 0.5 fl oz (15 mL)
• Artificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0.6%) – 0.5 fl oz (15 mL)

What Consumers Should Do

Consumers who have purchased any of the affected products are encouraged to review the product labeling carefully and monitor for any unusual symptoms such as redness, irritation, pain, or vision changes.

If any of these symptoms occur, medical attention should be sought promptly.

Even in the absence of symptoms, some consumers may choose to stop using the products out of caution, particularly those with sensitive eyes or pre-existing conditions.

Broader Safety Concerns

This recall highlights the importance of strict quality control in pharmaceutical manufacturing, especially for products that bypass the body’s natural defenses and are applied directly to vulnerable areas.

Sterility failures in eye care products have drawn increased scrutiny in recent years, as even isolated incidents can lead to widespread recalls and heightened regulatory oversight.

For now, health officials emphasize that while the risk appears limited, the recall serves as a precautionary step to ensure consumer safety while further investigation is carried out.

As more information becomes available about the source of the sterility concern, regulators and the manufacturer are expected to provide updates.